Daniel C. Baumgart
A5042526092- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Immunotherapy and Immune Responses
- Pregnancy and Medication Impact
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Immune Response and Inflammation
- Reproductive System and Pregnancy
- Medical and Health Sciences Research
- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- Diverticular Disease and Complications
- Anorectal Disease Treatments and Outcomes
- Liver Diseases and Immunity
- Gastrointestinal disorders and treatments
- Linguistic research and analysis
- Linguistic Education and Pedagogy
- Health and Medical Studies
- Systemic Lupus Erythematosus Research
- Immune Cell Function and Interaction
- Colorectal Cancer Screening and Detection
- Esophageal and GI Pathology
- Health Systems, Economic Evaluations, Quality of Life
University of Alberta
2018-2025
Charité - Universitätsmedizin Berlin
2012-2025
Humboldt-Universität zu Berlin
2011-2025
Human Factors (Norway)
2019
Centre Virchow-Villermé
2005-2013
Dartmouth–Hitchcock Medical Center
2009
Massachusetts General Hospital
2009
European Crohn's and Colitis Organisation
2009
KU Leuven
2009
Agaplesion Markus Hospital
2009
Principal changes with respect to the 2004 ECCO guidelines Ileocolonoscopy is recommended within first year after surgery where treatment decisions may be affected (Statement 8C). Thiopurines are more effective than mesalazine or imidazole antibiotics alone in post-operative prophylaxis 8F). ### 8.1 Epidemiology of Crohn's disease In natural history CD, intestinal resection almost unavoidable since about 80% patients require at some stage. Surgery unfortunately not curative as disease...
The management of patients with IBD requires evaluation objective tools, both at the time diagnosis and throughout course disease, to determine location, extension, activity severity inflammatory lesions, as well as, potential existence complications. Whereas endoscopy is a well-established uniformly performed diagnostic examination, implementation radiologic techniques for assessment still heterogeneous; variations in technical aspects degrees experience preferences exist across countries...
Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis.In this double-blind, placebo-controlled, randomised, phase 2 study, colitis who had not responded conventional therapy were recruited from 40 referral centres 11 countries. Eligible (aged 18-75 years; Mayo Clinic Score [MCS] 5 higher [or ≥6 USA]; disease extending 25 cm...
Chapter 4: Scores for Inflammatory Bowel Disease 4.1 Clinical and endoscopic scoring systems in IBD Statement 4.1.ECCO-ESGAR Diagnostics GL (2018) indices are useful standardizing disease activity.However, despite widespread use, no score has been validated clinical practice [EL5] ulcerative colitisThere several presently available to classify severity colitis (UC) within the multiple domains of activity, which aid objective assessment guide therapeutic monitoring strategies [1,2].Although...
Background & AimsMost patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after We performed a randomized trial to compare the ability of infliximab vs placebo prevent recurrence.MethodsWe evaluated efficacy in preventing postoperative recurrence 297 at 104 sites worldwide from November 2010 through May 2012. All study had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) groups...
Summary Background Vedolizumab (VDZ) is a humanised monoclonal IgG1 antibody targeting α 4 β 7 integrin. Aim To investigate the real‐world efficacy of vedolizumab for treatment Crohn's disease ( CD ) and ulcerative colitis UC ). Methods A consecutive cohort 212 adult IBD patients with active HBI >7/partial Mayo >4) newly receiving VDZ was prospectively recruited from academic 17 community centres. The primary endpoint clinical remission CRM ≤4, pMayo ≤1) in week 14. Secondary endpoints...
Toll-like receptors (TLRs) are key components of the innate immune system that trigger antimicrobial host defense responses. The aim present study was to analyze effects probiotic Escherichia coli Nissle strain 1917 in experimental colitis induced TLR-2 and TLR-4 knockout mice. Colitis wild-type (wt), knockout, mice via administration 5% dextran sodium sulfate (DSS). Mice were treated with either 0.9% NaCl or 10(7) E. twice daily, followed by determination disease activity, mucosal damage,...
We and others have reported the use of tacrolimus in refractory inflammatory bowel disease (IBD). Little is known about its long-term efficacy safety.In this retrospective, observational single center study charts 53 adult patients with steroid-dependent (n = 18) or steroid-refractory 35) IBD, Crohn's (CD) 11), ulcerative colitis (UC) 40), pouchitis (PC) 2) were reviewed. Tacrolimus (0.1 mg/kg body weight per day) was administered orally all initially intravenously 2 (0.01 day), aiming for...
It is assumed that esophageal adenocarcinoma the end result of a stepwise disease process transitions through gastroesophageal reflux (GERD) and Barrett's esophagus. The aim this study was to examine at what stage known risk factors exert their influence toward progression cancer.We enrolled 113 consecutive outpatients without GERD, 188 with 162 esophagus, 100 or high-grade dysplasia (HGD). All patients underwent standard upper endoscopy completed standardized questionnaire about social...
Background Vedolizumab, a monoclonal antibody targeting the α4β7-integrin, is effective in inducing and maintaining clinical remission Crohn's disease ulcerative colitis according to randomised trials. Aim To determine long-term effectiveness of vedolizumab real-world setting. Methods This observational registry assessed outcome patients treated with for clinically active (n = 67) or 60). Primary endpoint was (HBI ≤ 4/pMayo 1) at week 54. Secondary endpoints included response rates...
Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for treatment ulcerative colitis (UC). As a molecule, tofacitinib likely to cross placental barrier; however, information on effects outcomes limited. We report and newborn among patients in UC clinical studies with prenatal (maternal/paternal) exposure tofacitinib. Pregnancies maternal/paternal were identified reported 5 interventional (up March...
<h3>Objective</h3> Etrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration retention ulcerative colitis (UC). This randomised phase I study evaluated safety pharmacology etrolizumab patients with moderate to severe UC. <h3>Design</h3> In single ascending dose (SAD) stage, (0.3, 1.0, 3.0, 10 mg/kg intravenous, 3.0 subcutaneous (SC) or placebo) was administered...
Etrolizumab is a humanized monoclonal antibody against the β7 integrin subunit that has shown efficacy vs placebo in patients with moderate to severely active ulcerative colitis (UC). Patients colon tissues expressed high levels of αE gene (ITGAE) appeared have best response. We compared differences colonic expression ITGAE and other genes between who achieved clinical remission etrolizumab those did.We performed retrospective analysis data collected from 110 UC participated phase 2...